A Phase 3 interventional study of Nivolumab and Placebo in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 130 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.
Among the 142 studies testing nivolumab in Melanoma, this one is the 7th largest by enrollment, is one of 16 that started in 2019, is one of 19 in phase 3, reaches primary completion later than 4 of the 62 other live ones, and was the 75th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 20 · Phase 4 4
First in 2006; this study’s year is marked. 16 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 790 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.
Median enrollment 50 across the 142 interventional studies. Of the 62 that completed or were terminated, 35 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 142 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 75 interventional ones that give a count, is one of 8 that started in 2019, is one of 21 in phase 3, and was the 92nd registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
13 of the studies testing nivolumab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04309409Phase 3University Hospital, EssenAdjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma | 2027-09 |
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT03685890Vastra Gotaland RegionEvaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion | 2026-12-31 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 142 studies testing nivolumab in Melanoma, from their registry updates:
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab
Other: Placebo
Specified dose on specified days
Also known as: Opdivo
Specified dose on specified days
Recurrence Free Survival (RFS)
Recurrence Free Survival (RFS) is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurs first. For participants who remain alive and whose disease has not recurred or did not die, RFS will be censored on the date of last evaluable disease assessment. For those participants who remained alive and had no recorded post-randomization tumor assessment, RFS will be censored on the day of randomization.
Time frame: From randomization up to the date of first recurrence, new primary melanoma, or death (whatever the cause), whichever occurs first (up to 32 months)
Distant Metastasis-Free Survival (DMFS)
Investigator-assessed distant metastasis-free survival (DMFS) is defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. Participants with no baseline disease assessment, no on-study disease assessments and no death, and no distant metastasis and no death will be censored. Participants with no baseline disease assessment and no on-study disease assessments and death are censored on the date of randomization. Participants with no recurrence and no death will be censored on the date of their last evaluable disease assessment.
Time frame: From randomization up to the date of first distant metastasis or date of death (whatever the cause), whichever occurs first (up to approximately 32 months)
Duration of Treatment on Next Line Therapy Per Investigator Assessment
Duration of treatment is an investigator-assessed outcome of next-line therapy (NLT) defined as the time from first dose date of NLT to last dose date of NLT. Participants who did not stop the NLT were censored.
Time frame: From first dose date of next-line therapy to last dose date of next-line therapy (up to approximately 32 months)
Progression-Free Survival Through Next-Line Therapy
Progression-free survival through next-line therapy (PFS2) is defined as the time from randomization to recurrence/objective disease progression after the start of the next-line of systemic anti-cancer therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first. Participants who did not receive subsequent systemic anti-cancer therapy who died will be considered as having the event on the date of death. Participants who received subsequent systemic anti-cancer therapy who had a disease progression after the start of therapy will be considered as having the event on the date of disease progression. Participants who died or started second next-line therapy, the date of death or start date of second next-line therapy will be the event date, whichever is earlier. Participants who did not experience disease progression, death, or second next-line therapy will be censored on the last known alive date.
Time frame: From randomization to recurrence/objective disease progression after the start of the next-line therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first (up to approximately 32 months)
Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Number of Participants Experiencing Adverse Events Leading to Discontinuation
An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Number of Participants Experiencing Select Adverse Events
The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Number of Participants Experiencing Serious Adverse Events (SAEs)
A Serious Adverse Events (SAE) is defined as any untoward or unfavorable medical occurrence in a participants that results in death, is life threatening, or places the participant at immediate risk of death from the event as it occurred, requires or prolongs hospitalization, causes persistent or significant disability or incapacity, results in congenital anomalies or birth defects, and is another condition which investigators judge to represent significant hazards.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Number of Participants Experiencing Death
All study participants who died during the blinded phase of the study following treatment.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Number of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities in Selected Hematology Parameters
The number of participants experiencing Grade 3 or 4 laboratory abnormalities in the specific pre-determined hematology tests.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Number of Participants Experiencing Laboratory Abnormalities in Selected Liver Parameters
The number of participants experiencing laboratory abnormalities in the specific pre-determined liver tests.
Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Overall Survival (OS)
OS is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
Time frame: From randomization up to the date of death or the last date the participant was known to be alive
| Milestone | Nivolumab | Placebo |
|---|---|---|
| Started | 526 | 264 |
| Completed | 524 | 264 |
| Not completed | 2 | 0 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: Participant no longer meets study criteria | 1 | 0 |
| Milestone | Nivolumab | Placebo |
|---|---|---|
| Started | 524 | 264 |
| Completed | 257 | 158 |
| Not completed | 267 | 106 |
| Withdrew: Other reasons | 16 | 7 |
| Withdrew: Disease recurrence | 26 | 41 |
| Withdrew: Adverse event unrelated to study drug | 11 | 1 |
| Withdrew: Study drug toxicity | 94 | 7 |
| Withdrew: Participant no longer meets study criteria | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 6 | 2 |
| Withdrew: Withdrawal by subject | 18 | 7 |
| Withdrew: Participant request to discontinue study treatment | 29 | 0 |
| Withdrew: Ongoing treatment | 64 | 39 |
| Withdrew: Maximum clinical benefit | 1 | 2 |
| Milestone | Nivolumab | Placebo |
|---|---|---|
| Started | 2 | 30 |
| Completed | 2 | 28 |
| Not completed | 0 | 2 |
| Withdrew: Participant withdrew consent after re-baseline visit | 0 | 2 |
| Milestone | Nivolumab | Placebo |
|---|---|---|
| Started | 2 | 28 |
| Completed | 0 | 3 |
| Not completed | 2 | 25 |
| Withdrew: Disease progression/recurrence | 0 | 5 |
| Withdrew: Decision by principal investigator | 0 | 1 |
| Withdrew: Study drug toxicity | 0 | 2 |
| Withdrew: Ongoing treatment | 2 | 17 |
Recurrence Free Survival (RFS) is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurs first. For participants who remain alive and whose disease has not recurred or did not die, RFS will be censored on the date of last evaluable disease assessment. For those participants who remained alive and had no recorded post-randomization tumor assessment, RFS will be censored on the day of randomization.
| Months | Nivolumab | Placebo |
|---|---|---|
| Recurrence Free Survival (RFS) | NA (28.52 to NA) | NA (21.62 to NA) |
Investigator-assessed distant metastasis-free survival (DMFS) is defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. Participants with no baseline disease assessment, no on-study disease assessments and no death, and no distant metastasis and no death will be censored. Participants with no baseline disease assessment and no on-study disease assessments and death are censored on the date of randomization. Participants with no recurrence and no death will be censored on the date of their last evaluable disease assessment.
| Months | Nivolumab | Placebo |
|---|---|---|
| Distant Metastasis-Free Survival (DMFS) | NA (28.52 to NA) | NA (NA to NA) |
Duration of treatment is an investigator-assessed outcome of next-line therapy (NLT) defined as the time from first dose date of NLT to last dose date of NLT. Participants who did not stop the NLT were censored.
| Months | Nivolumab | Placebo |
|---|---|---|
| Duration of Treatment on Next Line Therapy Per Investigator Assessment | 4.17 (2.69 to 8.38) | 11.14 (5.85 to NA) |
Progression-free survival through next-line therapy (PFS2) is defined as the time from randomization to recurrence/objective disease progression after the start of the next-line of systemic anti-cancer therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first. Participants who did not receive subsequent systemic anti-cancer therapy who died will be considered as having the event on the date of death. Participants who received subsequent systemic anti-cancer therapy who had a disease progression after the start of therapy will be considered as having the event on the date of disease progression. Participants who died or started second next-line therapy, the date of death or start date of second next-line therapy will be the event date, whichever is earlier. Participants who did not experience disease progression, death, or second next-line therapy will be censored on the last known alive date.
| Months | Nivolumab | Placebo |
|---|---|---|
| Progression-Free Survival Through Next-Line Therapy | NA (NA to NA) | NA (NA to NA) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Nivolumab | Placebo |
|---|---|---|
| Any Grade | 502 | 229 |
| Grade 3-4 | 115 | 32 |
An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
| Participants | Nivolumab | Placebo |
|---|---|---|
| Number of Participants Experiencing Adverse Events Leading to Discontinuation | 91 | 9 |
The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
| Participants | Nivolumab | Placebo |
|---|---|---|
| Endocrine | 116 | 14 |
| Gastrointestinal | 122 | 41 |
| Hepatic | 86 | 35 |
| Pulmonary | 10 | 1 |
| Renal | 30 | 10 |
| Skin | 217 | 64 |
| Hypersensitivity/Infusion Reactions | 33 | 2 |
A Serious Adverse Events (SAE) is defined as any untoward or unfavorable medical occurrence in a participants that results in death, is life threatening, or places the participant at immediate risk of death from the event as it occurred, requires or prolongs hospitalization, causes persistent or significant disability or incapacity, results in congenital anomalies or birth defects, and is another condition which investigators judge to represent significant hazards.
| Participants | Nivolumab | Placebo |
|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) | 74 | 29 |
All study participants who died during the blinded phase of the study following treatment.
| Participants | Nivolumab | Placebo |
|---|---|---|
| Number of Participants Experiencing Death | 14 | 8 |
The number of participants experiencing Grade 3 or 4 laboratory abnormalities in the specific pre-determined hematology tests.
| Participants | Nivolumab | Placebo |
|---|---|---|
| PLATELET COUNT | 1 | 0 |
| LYMPHOCYTES (ABSOLUTE), LOCAL LAB | 5 | 4 |
| ABSOLUTE NEUTROPHIL COUNT | 0 | 1 |
The number of participants experiencing laboratory abnormalities in the specific pre-determined liver tests.
| Participants | Nivolumab | Placebo |
|---|---|---|
| ALT OR AST > 3XULN | 29 | 5 |
| ALT OR AST > 5XULN | 16 | 2 |
| ALT OR AST > 10XULN | 6 | 0 |
| ALT OR AST > 20XULN | 2 | 0 |
| TOTAL BILIRUBIN > 2XULN | 3 | 5 |
| ALP > 1.5XULN | 20 | 1 |
OS is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
Results for this outcome have not been posted.
Collected over Participants were assessed for all-cause mortality from their randomization to primary completion, (up to approximately 32 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab | 14/526 (2.7%) | 95/524 (18.1%) | 464/524 (88.5%) |
| Placebo | 8/264 (3%) | 37/264 (14%) | 194/264 (73.5%) |
| Open-Label Nivolumab | 2/32 (6.3%) | 5/30 (16.7%) | 20/30 (66.7%) |
| Event | Nivolumab | Placebo | Open-Label Nivolumab |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 4/524 | 0/264 | 2/30 |
| ColitisGastrointestinal disorders | 4/524 | 1/264 | 1/30 |
| Hiatus herniaGastrointestinal disorders | 0/524 | 1/264 | 1/30 |
| VolvulusGastrointestinal disorders | 0/524 | 0/264 | 1/30 |
| General physical health deteriorationGeneral disorders | 0/524 | 0/264 | 1/30 |
| PneumoniaInfections and infestations | 2/524 | 0/264 | 1/30 |
| Aspartate aminotransferase increasedInvestigations | 4/524 | 1/264 | 1/30 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/524 | 0/264 | 1/30 |
| Acute kidney injuryRenal and urinary disorders | 3/524 | 1/264 | 1/30 |
| UrticariaSkin and subcutaneous tissue disorders | 0/524 | 1/264 | 1/30 |
| Event | Nivolumab | Placebo | Open-Label Nivolumab |
|---|---|---|---|
| FatigueGeneral disorders | 140/524 | 67/264 | 6/30 |
| DiarrhoeaGastrointestinal disorders | 121/524 | 44/264 | 3/30 |
| PruritusSkin and subcutaneous tissue disorders | 107/524 | 29/264 | 3/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 87/524 | 31/264 | 3/30 |
| NauseaGastrointestinal disorders | 78/524 | 30/264 | 1/30 |
| Dry mouthGastrointestinal disorders | 41/524 | 10/264 | 4/30 |
| AstheniaGeneral disorders | 63/524 | 25/264 | 4/30 |
| PyrexiaGeneral disorders | 35/524 | 13/264 | 4/30 |
| COVID-19Infections and infestations | 46/524 | 23/264 | 4/30 |
| RashSkin and subcutaneous tissue disorders | 69/524 | 26/264 | 2/30 |
| Age, Continuous(Years) | Nivolumab | Placebo | Total |
|---|---|---|---|
| Mean | 59.9 ± 13.9 | 59.3 ± 13.6 | 59.7 ± 13.8 |
| Sex: Female, Male(Participants) | Nivolumab | Placebo | Total |
|---|---|---|---|
| Female | 204 | 103 | 307 |
| Male | 322 | 161 | 483 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 6 | 17 |
| Not Hispanic or Latino | 317 | 140 | 457 |
| Unknown or Not Reported | 198 | 118 | 316 |
| Race (NIH/OMB)(Participants) | Nivolumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 515 | 262 | 777 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 1 | 9 |
Showing the first 100 of 130 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Oct 2019 to primary completion in Jun 2022, 32 months.
Results were first posted in Jul 2023, 1 year after primary completion.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 32 months is below that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab